ImmunoINSIGHTS commercial update

RNS Number : 6542B

Oncimmune Holdings PLC

15 February 2022

 

15 February 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

ImmunoINSIGHTS commercial update

Further contract signed under Master Services Agreement with leading, top five global pharmaceutical company to profile patients using ImmunoINSIGHTS service

New office established at the Cambridge Innovation Center in Boston
to assist with business development efforts

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces it has signed a further commercial contract under its existing master services agreement ("MSA") with a top five global pharmaceutical company, profiling over 350 chronic idiopathic urticaria¹ ("CIU") patients for biomarkers to characterise disease and stratify patients for therapy.

This follows on from the previous announcement on the 21 December 2021, that ImmunoINSIGHTS had signed an MSA with a leading global pharmaceutical company, under which an initial commercial contract was signed to provide autoantibody biomarker services.

Under the terms of this latest contract, ImmunoINSIGHTS will profile the Immunoglobulin G ("IgG") autoantibodies present in over 350 CIU patients. Profiling prior to and after treatment will allow assessment of whether these biomarkers can better characterise the disease, and in turn lead to the stratification of patients for response to therapy. The study will also uncover insights to support the clinical development of a therapeutic for CIU.

Oncimmune will customise its existing SeroTag^TM autoimmune disease discovery array to add specific antigens related to CIU. If successful, a panel of the best performing autoantibodies can then be validated on samples from additional trials performed by our client.

The previously announced project for this client to measure Immunoglobulin   E ("IgE") autoantibodies is progressing to plan and on schedule. Once finalised, the samples from this IgG study will also be profiled for IgE autoantibodies, which will in turn contribute to our knowledge of autoantibody profiles in CIU. The second agreement with this global pharmaceutical partner, further validates the value of Oncimmune's autoantibody biomarker profiling technology in supporting pharmaceutical and biotechnology companies in their clinical development programmes.

Additionally, Oncimmune today announces that the Company has recently established an office at the Cambridge Innovation Center ("CIC"), Kendall Square, Boston, USA which will be the new base for our Chief Business Officer, Cameron Barnard, and enables the ImmunoINSIGHTS commercial team to operate in closer proximity to many of the Company's North American pharma clients.

Dr Adam M Hill, CEO of Oncimmune said:  "We are delighted to announce this second, follow-on, contract with a leading global pharmaceutical group. This contract, along with others previously announced and other unannounced contracts, further demonstrates the growing commercial momentum behind our ImmunoINSIGHTS platform. The establishment of an office at CIC will facilitate more efficient business development interactions for our North American clients. We look forward to updating shareholders on operational progress when we announce our interim results for the period ended to 30 November 2021 later this month."

¹ CIU, also known as hives, is a skin disease which is often caused by an allergic reaction to food or drugs. In a small number of cases, the disease is chronic and of unknown cause.

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit  www.oncimmune.com

What is SeroTag^TM?

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers can help stratify patients in multiple cancer indications and with different autoimmune diseases.

This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally invasive liquid biopsies. SeroTag analyses autoantibodies-some of the most stable analytes-and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.

The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune's NavigAID^TM disease-specific stratification panels. These precision medicine tools which are enabling patient and disease stratification and support therapeutic development.

 

END

 

 

MSCUSRRRUOUUAUR